FibroGen Inc. Reduces Cash Balance Requirement with Fourth Amendment to Financing Agreement
FibroGen Inc. has announced the entry into a fourth amendment to its financing agreement with investment funds managed by Morgan Stanley Tactical Value. This amendment, dated August 12, 2025, further reduces the minimum qualified cash balance that FibroGen is required to maintain in its U.S. deposit or securities accounts from $18.75 million to $15 million. The agreement, originally dated April 29, 2023, and amended multiple times, involves Wilmington Trust National Association acting as the administrative agent for the lenders. The amendment aims to provide FibroGen with increased financial flexibility. Further details can be found in the full text of the Fourth Amendment, filed as Exhibit 10.1 to FibroGen's Current Report on Form 8-K.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-108280), on August 14, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。